Aardvark Therapeutics (AARD) announced the appointments of key members of its leadership team, including Timothy Kieffer as chief scientific officer; Danny Villeneuve as chief commercial officer; Terrie Kellmeyer as senior VP, regulatory affairs and Christian Zapf as general counsel. Kieffer previously served as CSO at ViaCyte. Villeneuve most recently served as EVP, CCO for Ironshore Pharmaceuticals.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AARD:
- Aardvark Therapeutics Inc trading resumes
- Aardvark Therapeutics Inc trading halted, volatility trading pause
- Promising Future for Aardvark Therapeutics: Buy Rating Backed by Strong Pipeline and Financial Health
- Positive Outlook for Aardvark Therapeutics Amid Favorable Regulatory and Market Conditions
- Aardvark Therapeutics price target raised to $26 from $22 at BofA